drugset / Trial / NCT00589628

Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis

NCT00589628

RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to examine the efficacy of infliximab for the treatment of persistent uveitis in children. Participants (4-18 years of age) will be randomly assigned to either 5mg/kg or 10mg/kg dose of infliximab to be administered by intravenous infusion at four week intervals. Participant responses will be measured at at four to eight week intervals for up to ten months.

Timeline

Start
2007-09
Primary completion
2010-12
Completion
2010-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Infliximab Monoclonal antibody 5 mg/kg Intravenous
Comparator Infliximab Monoclonal antibody 10 mg/kg Intravenous

Indications